Event Type
Disclosure
Mandatory
Variant
8-K
Entry into a Material Definitive Agreement. Binding Term Sheet On March 2, 2026, Kairos Pharma, Ltd., a Delaware corporation (the “Company”) entered into a bind
, including Exhibits 99.1, is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exch
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description of Document 10.1 Term Sheet, dated March 2, 2026, by and between the Company and Celyn